IMMIX BIOPHARMA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
IMMIX BIOPHARMA, INC. (IMMX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $910.64 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $910.64K, a 95.94% increase year-over-year.
- IMMIX BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $508.06K, a 15.62% decline year-over-year.
- IMMIX BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $402.97K, a 35.91% decline year-over-year.
- IMMIX BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $464.75K, a 13.19% decline year-over-year.
- IMMIX BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.93M, a 19.22% decline from fiscal 2024.
- IMMIX BIOPHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.39M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $910.64K 10-Q · filed 2026-08-07 | $1.42M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $508.06K 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $1.93M 10-K/A · filed 2026-03-27 | |||
| 2025-09-30 | $402.97K 10-Q · filed 2025-11-07 | $867.72K derived: sum of 2 quarters · filed 2026-08-07 | $1.47M derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-06-30 | $464.75K 10-Q · filed 2026-08-07 | $1.07M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $602.11K 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $2.39M 10-K/A · filed 2026-03-27 | |||
| 2024-09-30 | $628.81K 10-Q · filed 2025-11-07 | $1.16M derived: sum of 2 quarters · filed 2025-11-07 | $1.78M derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $535.35K 10-Q · filed 2025-11-07 | $1.15M derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $615.89K 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |